Patents Represented by Attorney, Agent or Law Firm David P. Lentini
-
Patent number: 6262098Abstract: Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.Type: GrantFiled: August 6, 1999Date of Patent: July 17, 2001Assignee: Chiron CorporationInventors: Verena D. Huebner, Xiaodong Lin, Ian James, Liya Chen, Manoj Desai, Jennifer C. Moore, Beata Krywult, Thayalan Navaratnam, Rajinder Singh, Rob Trainor, Liang Wang
-
Patent number: 6251433Abstract: This invention relates compositions and methods for increasing the uptake of polynucleotides into cells. Specifically, the invention relates to vectors, targeting ligands, and polycationic agents. The polycationic agents are capable of (1) increasing the frequency of uptake of polynucleotides into a cell, (2) condensing polynucleotides; and (3) inhibiting serum and/or nuclease degradation of polynucleotides.Type: GrantFiled: August 13, 1997Date of Patent: June 26, 2001Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Nathalie Dubois-Stringfellow, Varavani Dwarki, Michael A. Innis, John E. Murphy, Fred E. Cohen, Tetsuo Uno
-
Patent number: 6197332Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.Type: GrantFiled: August 12, 1998Date of Patent: March 6, 2001Assignee: Chiron CorporationInventors: Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
-
Patent number: 6192477Abstract: A method for performing secure communication between a first user's computer and second remote computer over a computer network is described. According to one embodiment of this aspect, the data space of the first computer is partition into a first secure portion and a second network interface portion. Communication is established between the first and a second computer, and redirection and filter mechanisms are initialized. An instruction is received by the first computer, analyzed by the redirection mechanism, and passed to the filter if the instruction is a protected instruction. The protected instruction is verified by the filter and processed if the verification is successful.Type: GrantFiled: February 2, 1999Date of Patent: February 20, 2001Assignee: Dagg LLCInventor: David Corthell
-
Patent number: 6188969Abstract: A computer-implemented statistical technique is provided for normalizing the response curves of multiple measurement methods. The end result is a group of response curves, one for each measurement method under consideration, which depend on a common independent variable—the actual physical property being measured by the methods. The results are provided as a collection of equations, curves, and/or tables (a “nomogram”) to facilitate conversion of measured values from one method to measured values from a second method. In the technique, data is provided for each of the methods being normalized. The input data includes measured values from common samples which are analyzed by two or more of the methods under consideration. The technique also requires assumptions or approximations of the true physical property values for each of the samples used to generate the data. Still further, the technique requires assumptions of the mathematical form of the response curves (e.g., linear, sigmoidal, etc.Type: GrantFiled: February 26, 1998Date of Patent: February 13, 2001Assignee: Chiron CorporationInventor: James M. Minor
-
Patent number: 6153618Abstract: Compounds of formula 1: ##STR1## wherein R.sub.1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;R.sub.2 is hydroxy, amino, or lower alkoxy;R.sub.3 is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amnino-acyl;R.sub.4 is H or lower alkyl; and pharmaceutically acceptable salts and esters thereof; are effective inhibitors of GSK3.Type: GrantFiled: October 10, 1997Date of Patent: November 28, 2000Assignee: Chiron CorporationInventors: Peter Schultz, David B. Ring, Stephen D. Harrison, Andrew M. Bray
-
Patent number: 6097831Abstract: Methods and systems for verifying the volume of a reagent dispensed into an affinity assay vessel are described. In one embodiment, a method is for verifying the volume of a reagent dispensed into an affinity assay vessel described in which a fluid sample is deposited into a vessel that includes a reaction chamber and a volume determination reference point. The reaction chamber further includes a test strip. According to one embodiment, the dispensed fluid is agitated to promote contact between the fluid and a test strip disposed within the reaction chamber. The relative positions of the volume determination reference point and an edge of the meniscus of the dispensed fluid are then determined such that the meniscus of the dispensed fluid is not penetrated. The volume of the dispensed fluid is determined from these relative positions.Type: GrantFiled: October 14, 1997Date of Patent: August 1, 2000Assignee: Chiron CorporationInventors: Henry J. Wieck, Paul C. Dahlstrom, Dennis W. Nixon
-
Patent number: 6057117Abstract: The invention provides for use of selective inhibitors of GSK3 for treatment of diseases that are mediated by GSK3 activity, including non-insulin dependent diabetes mellitus (NIDDM) and Alzheimer's disease. Also described are methods of identifying inhibitors of GSK3 activity. The selective GSK3 inhibitor can be a peptide, peptoid, small organic molecule, or polynucleotide.Type: GrantFiled: March 12, 1999Date of Patent: May 2, 2000Assignee: Chiron CorporationInventors: Stephen D. Harrison, David B. Ring
-
Patent number: 6044218Abstract: A system for a live applet or application development environment includes software that cooperatively promotes and permits immediate socialization of new components with existing components as the new components are instantiated or dropped onto the development desktop. This is achieved by registering a new component being instantiated with the development environment's kernel. Registration, in turn, invokes an initialization method derived from the class template that yielded the new component. The initialization method appropriately personalizes the new component when it executes its associated logic. The initialization method provide an editor for the new component if its properties are to be made editable. The software environment, its kernel, templates, components, editor and methods are preferably programmed in the Java programming language or a Java compatible language.Type: GrantFiled: January 31, 1997Date of Patent: March 28, 2000Assignee: Sun Microsystems, Inc.Inventor: Antony Azio Faustini
-
Patent number: 6030940Abstract: Effective urokinase-type plasminogen activator receptor antagonists have sequences selected from the group LNFGQYLWYT, LCFGCYLWYT, LNFGCYLWCT, LNFGQYLnAYT, LNFdSQYLWYT, LCFGCYLWY, LNFdSQYLnAYT, LNFGdCYLWCT, LCFdSCYLWYT, LCFdSCYLnAYT, LNFdSCYLWCT, or active analogs or active portions thereof.Type: GrantFiled: February 12, 1997Date of Patent: February 29, 2000Assignee: Chiron CorporationInventors: Steven Rosenberg, Kerry L. Spear, Robert Valerio, Andrew Bray
-
Patent number: 5913065Abstract: Method, system and article of manufacture for creating hierarchical folder components for use with in holding other object oriented based components, including other folder components, and component assemblies. Each hierarchical folder is provided with an editor that pops up upon its instantiation and permits a user to edit the folder component name as well as the number and type of ports assigned to the folder component.Type: GrantFiled: January 31, 1997Date of Patent: June 15, 1999Assignee: Sun Microsystems, Inc.Inventor: Antony Azio Faustini
-
Patent number: 5874444Abstract: Inhibition of the enzyme poly (ADP-ribose) polymerase can delay the onset of senescence and inhibitors of the enzyme can be used to treat diseases caused or exacerbated by cellular senescence.Type: GrantFiled: August 27, 1996Date of Patent: February 23, 1999Assignee: Geron CorporationInventor: Michael David West
-
Patent number: 5863936Abstract: Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds characterized by the following structure: ##STR1## and their pharmaceutically acceptable salts. Y is selected from the group consisting of oxygen, sulfur, sulfonyl, sulfinyl, and --NR.sub.7 --. R.sub.1 is --TR.sub.8, where T is --C(X.sub.1)-- or --SO.sub.2 --, and R.sub.8 is selected from the group consisting of --OR.sub.9, --NHNHSO.sub.2 R.sub.9, --NHNHC(X.sub.2)OR.sub.9, --NR.sub.9 R.sub.10, --NHNHC(X.sub.2)NR.sub.9 R.sub.10, --NHCR.sub.9 R.sub.10 C(X.sub.2)NR.sub.11 R.sub.12, --NHC(X.sub.2)NR.sub.9 R.sub.10, and the piperazinyl moiety shown below: ##STR2## where n is 0 or 1, and Q.sub.n, for n=1, is --SO.sub.2 --, --C(X.sub.2)-- or --C(X.sub.2)NR.sub.10 --. R.sub.2 -R.sub.Type: GrantFiled: October 27, 1995Date of Patent: January 26, 1999Assignee: Geron CorporationInventors: Federico C.A. Gaeta, Adam A. Galan, Elaine C. Stracker
-
Patent number: 5770613Abstract: Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds that are derivatives of pyridine aldehydes, thioaldehyde, acetals, or thioacetals. Such compounds are characterized by the following structure: ##STR1## X.sub.1 is selected from the group consisting of oxygen, sulfur, sulfone, sulfinyl, and --NR-- where R is hydrogen, alkyl, aryl, and aralkyl. R.sub.1 is --Y.sub.n R.sub.6, in which n is an integer between 0 and 10 and each Y.sub.n for n greater than 0 independently is methylene, methine, or quarternary carbon. R.sub.6, for any value of n (i.e.Type: GrantFiled: September 29, 1995Date of Patent: June 23, 1998Assignee: Geron CorporationInventors: Federico C. A. Gaeta, Elaine C. Stracker
-
Patent number: 5767278Abstract: Compounds for treating cancer and other diseases involving telomerase activity are characterized by the following structure: ##STR1## Such compounds include those for which X.sub.1 is oxygen, sulfur, sulfone, or sulfinyl, and R.sub.1 is --Y.sub.n R.sub.6, where n is an integer between 0 and 10 and each Y.sub.n independently is methylene, methine, or quaternary carbon. R.sub.6, is alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, alkylcarbonyl, arylcarbonyl, heteroalkylcarbonyl, heteroaralkylcarbonyl, aralkylcarbonyl, arninocarbonyl, alkylarninocarbonyl, arylaminocarbonyl, dialkylaminocarbonyl, diarylaminocarbonyl, arylalkylaminocarbonyl, carboxyl, carboxaldehyde, alkoxycarbonyl, aryloxycarbonyl, sulfo, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, or arylsulfinyl. R.sub.6 can also be a linker selected from the group consisting of alkyl, aryl, and heterocycle. R.sub.Type: GrantFiled: October 6, 1995Date of Patent: June 16, 1998Assignee: Geron CorporationInventors: Federico C.A. Gaeta, Elaine C. Stracker
-
Patent number: 5760062Abstract: Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds that are derivatives of pyrido?b!thiophenes, pyrido?b!furans, pyridine ethers or pyridine thioethers. Such compounds are characterized by the following structure: ##STR1## X.sub.3 is oxygen or sulfur; and the double dashed lines between X.sub.4 and X.sub.5 indicate an optional double bond, which, when present, forms a fused, bicyclic pyrido?b!furan or pyrido?b!thiophene ring system, depending upon whether X.sub.3 is oxygen or sulfur, respectively. When the double bond is not present, the compound is a monocyclic pyridine ether or thioether, again depending upon whether X.sub.3 is oxygen or sulfur. X.sub.4 is --CH.sub.2 R.sub.21 or --CR.sub.21 --, where R.sub.Type: GrantFiled: April 18, 1995Date of Patent: June 2, 1998Assignee: Geron CorporationInventors: Federico C.A. Gaeta, Adam A. Galan, Michael R. Kozlowski, Karen R. Prowse, Elaine C. Stracker, Patricia A. Peterli-Roth
-
Patent number: 5703116Abstract: Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds that are derivatives of benzo?b!thiophenes. Such compounds are characterized by the following structure: ##STR1## In this compound, R.sub.1 is selected from the group consisting of --OR.sub.7, --NR.sub.8 R.sub.9, --NHNR.sub.10 R.sub.11, --NHNHC(X.sub.2)NHR.sub.12, --NHSO.sub.2 NR.sub.8 R.sub.9, --NHNHC(O)R.sub.12, --NHNHSO.sub.2 R.sub.12 and --NHC(O)NR.sub.8 R.sub.9. R.sub.7 -R.sub.12 are selected independently from the group consisting of hydrogen, alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl. X.sub.1 and X.sub.2 are selected independently from the group consisting of oxygen and sulfur. R.sub.2 is hydrogen or halogen. R.sub.3 -R.sub.6 are selected independently from the group consisting of hydrogen, halogen, hydroxyl, --NR.sub.8 R.sub.9, nitro, cyano, alkoxyl, lower alkyl, aryl and aryloxyl.Type: GrantFiled: April 18, 1995Date of Patent: December 30, 1997Assignee: Geron CorporationInventors: Federico C. A. Gaeta, Adam Antoni Galan, Elaine C. Stracker
-
Patent number: 5656638Abstract: Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds characterized by the following structure: ##STR1## and its pharmaceutically acceptable salts. Z is selected from the group consisting of oxygen, sulfur, sulfone, sulfinyl and --NR--, where R selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl. R.sub.1 is --Y.sub.n R.sub.6, where n is an integer between 0 and 10 and each Y.sub.n for n greater than 0 independently is methylene, methine, or quaternary carbon, and R.sub.Type: GrantFiled: November 7, 1995Date of Patent: August 12, 1997Assignee: Geron CorporationInventors: Federico C. A. Gaeta, Elaine C. Stracker, Patricia A. Peterli-Roth
-
Patent number: 5635597Abstract: Peptides that bind to the Interleukin-2 (IL-2) receptor subunits IL-2R.alpha., IL-2R.beta. and IL-2R.gamma., and inhibit the binding of IL-2 to these important receptors, are described. The invention also includes methods for treating diseases related to the activation of these receptors, as well as the receptors for IL-4, -7 and -13. In addition, the present invention also includes methods for assaying for the presence of these receptors on cell surfaces.Type: GrantFiled: May 27, 1994Date of Patent: June 3, 1997Assignee: Affymax Technologies, N.V.Inventors: Ronald W. Barrett, Tania Chernov-Rogan, Ann M. Davis